CDEK
← All drugs Report issue

durvalumab

Trade name: imfinzi

mAbapprovedBreakthrough Therapy FDA

Approved

May 1, 2017

Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1). — Wikipedia

Clinical trial activity

735 trials · 455 clinical orgs · 1 marketing orgs

Phase 1
232
Phase 2
582
Phase 3
94
Phase 4
5

Earliest trial started Aug 29, 2012 (NCT01693562)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    AstraZeneca — Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2014

    AstraZeneca — Earliest Phase 3 Sponsor(trial)

  4. May 1, 2017

    AstraZeneca — Earliest FDA Approval

  5. May 1, 2017

    AstraZeneca — Marketing Organization

  6. May 1, 2017

    AstraZeneca — NDA Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewAcceleratedBreakthroughMay 1, 2017

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Availability
Prescription Only
Multi-specific
No
Payload
Staphylococcal enterotoxin A

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • duravalumab
  • durvalumab
  • durvalumab
  • durvalumab
  • durvalumab
  • durvalumab
  • imfinzi
  • imfinzi
  • iph5401 and durvalumab
  • medi4736
  • medi-4736
  • medi-4736
  • nacolomab tafenatox

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07288034Phase 2Sep 21, 2026City of Hope National Medical Center, National Cancer Institute (NCI)
NCT07247786Phase 2Mar 15, 2026Fundación GECP, Grupo Español de Cáncer de Pulmón
NCT07226063Phase 2Feb 28, 2026Case Western Reserve University, Exelixis
NCT07122089Phase 2Jan 2, 2026Boston Scientific Corporation, Center Eugene Marquis
NCT07269158Phase 1/Phase 2 (Phase 2)Dec 31, 2025Yonsei University
NCT07221253Phase 3Dec 31, 2025AstraZeneca
NCT07196384Phase 1Dec 15, 2025University of Groningen
NCT07195695Phase 3Dec 5, 2025Boehringer Ingelheim
NCT06769126Phase 2Dec 1, 2025National Cancer Institute (NCI), SWOG Cancer Research Network
NCT07229625Phase 3Nov 30, 2025Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07172412Phase 2Nov 30, 2025Tianjin Medical University
NCT06904170Phase 2/Phase 3 (Phase 3)Nov 30, 2025AstraZeneca, Center Eugene Marquis, UNICANCER
NCT07174570Phase 2Nov 28, 2025Emory University, National Cancer Institute (NCI)
NCT07166406Phase 3Nov 27, 2025NRG Oncology
NCT07107750Phase 1Oct 31, 2025Curis, Washington University in St. Louis
NCT07175441Phase 2Oct 31, 2025Riboscience, LLC.
NCT06954480Phase 2Oct 27, 2025AstraZeneca, University of London
NCT06880523Phase 2Oct 21, 2025AstraZeneca, Canadian Cancer Trials Group, Fondazione Giovanni Pascale
NCT07111546Phase 2Oct 20, 2025Fudan University, Nanjing Leads Biolabs Co.,Ltd
NCT06994299Phase 2Oct 1, 2025Cornell University
Showing 20 of 735 trials
Page 1 / 37

Organizations

Research & Development (455)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstraZenecaFor profit33911052013
National Cancer Institute (NCI)Government612642014
MedImmuneFor profit542522012
University of Texas at HoustonAcademic/Hospital342532014
University of TorontoAcademic/Hospital201032015
CelgeneFor profit191022015
Harvard UniversityAcademic/Hospital181032015
Seoul National UniversityAcademic/Hospital171232014
Canadian Cancer Trials GroupAcademic/Hospital161532014
Cornell UniversityAcademic/Hospital151122013
Chinese Academy of Medical SciencesAcademic/Hospital121042020
Sungkyunkwan UniversityAcademic/Hospital12812016
Johns Hopkins UniversityAcademic/Hospital11732017
Daiichi SankyoFor profit10132020
Institut Gustave RoussyAcademic/Hospital10532014
Yonsei UniversityAcademic/Hospital10912016
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital9722017
UNICANCERAcademic/Hospital9822014
Cancer Research InstituteAcademic/Hospital8022013
Hoosier Cancer Research NetworkAcademic/Hospital8512017
455 organizations
Page 1 / 23

Marketing (2)

OrganizationOrg typeRelationshipDate
AstraZenecaFor profitMKTGMay 1, 2017
AstraZenecaFor profitNDAMay 1, 2017